GSK (NYSE:GSK) has taken an early lead in the race for respiratory syncytial virus (RSV) vaccine dominance, overtaking Pfizer Inc (NYSE:PFE), which previously dominated the COVID-19 vaccine market.
Receive notifications of the latest news, articles and much more! Continue
GSK’s RSV vaccine has gained significant traction in the United States, with IQVIA data revealing that it accounts for nearly two-thirds of RSV injections administered since early September.
This early success can be attributed to GSK’s strategic partnership with CVS Health Corp (NYSE:CVS), the largest pharmacy chain in the United States and a key player in the retail vaccine market.
You can also read: Pfizer discrimination against whites? Do No Harm revives lawsuit
The exclusive availability of GSK’s RSV vaccine at CVS Health has given the British drugmaker a competitive advantage, Reuters noted, citing analysts and industry experts.
Price considerations also appear to play a role, with GSK’s vaccine listed at a slight discount compared to Pfizer’s offering. The price point may be influencing independent pharmacists’ decisions in favor of GSK’s product.
As both companies look to expand their vaccine sales, these shots represent a potential source of revenue to counter upcoming generic competition faced by older drugs like Pfizer’s Ibrance and GSK’s Dovato.
You can also read: GSK’s Arexvy: Europe’s first RSV vaccine for older adults
While GSK’s early lead is significant, it remains to be seen how future decisions by major drugstore chains like Walgreens Boots Alliance Inc (NASDAQ:WBA), Walmart Inc (NYSE:WMT), y Rite Aid Corp.(OTC: RADCQ) may influence the RSV vaccine outlook.
GSK stock movement
GSK shares rose 2.24% to $35.34 at last check on Monday.
Disclaimer: This content was partially produced with the help of artificial intelligence tools and was reviewed and published by Benzinga editors.
You can also read: Pfizer profit forecast
2023-10-30 17:30:00
#GSK #leads #RSV #vaccine #market #United #States #Benzinga #Spain
